A rapid method has been developed for the determination of silver arsenite As(III), dimethylated arsenic DMA, monomethylated arsenic MMA, and arsenate As(V) in algae sample using liquid chromatography coupled with hydride generation atomic fluorescence spectrometry (LC-HG-AFS). Types, flow rate and pH of mobile phase were optimized. Under the optimal conditions, there were good linear relationships in the range of 0 -200 µg L-1 with correlation coefficients larger than 0.9995. The limits of detection and quantification of As(III), DMA, MMA, and As(V) were 0.005- 0.010 mg kg-1 and 0.019-0.034 mg kg-1, respectively. The recoveries at three spiked levels of 0.02, 0.5 and 1.0 mg kg-1 were in the range of 93-105 % with relative standard deviations (RSD, n=6) of 3.6%-6.2%. The proposed method was successfully applied in the determinaton of four arsenic species in algae sample. The developed method is simple, higher precision, stable data collection, and shorter separation time, and could be applied in the speciation and study of arsenic species in algae.
OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2–ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.
Abstract: We report an 80-year-old male patient with severe rheumatoid arthritis who was treated with tripterygium glycoside, an immunosuppressive agent made from the extract of a Chinese medicinal herb called Tripterygium wilfordii Hook F. The patient had no apparent skin lesions before the treatment, but he developed aggressive hyperkeratotic lesions with rapid progression after using tripterygium glycoside. He was repeatedly diagnosed with eczema, but treatment failed to achieve efficacy. Interestingly, a microscopic examination of the lesions revealed numerous scabies mites and eggs. Thus, we confirmed the diagnosis of Norwegian scabies infection. Treated with crotamiton 10% cream and 10% sulfur ointment for one month, the patient's clinical symptoms disappeared.